NEEDHAM, Massachusetts, October 11 /PRNewswire-FirstCall/ -- Oridion Systems, Ltd. - (SWX: ORIDN) introduces Smart Capnography(TM), a major step forward in improving patient safety.
This new launch takes place at this week's American Society of Anesthesiologists in San Francisco, CA.
Smart Capnography combines Oridion's most advanced Microstream(R) technology with its new SARA(TM) software for improved alarm management. Microstream allows the clinician to simultaneously monitor ventilation with end tidal carbon dioxide as well as monitor the patient's true respiratory rate. New clinical studies show that SARA, which stands for Smart Alarm Respiratory Analysis, safely reduces alarms by 55%.
Smart Capnography is being launched in response to last year's call from the Anesthesia Patient Safety Foundation (APSF) for improved patient monitoring, including continuous carbon dioxide monitoring for patients receiving patient controlled anesthesia (PCA). Numerous clinical studies such as have demonstrated conclusively that carbon dioxide monitoring provides the earliest indication of a change in a patient's breathing status. In fact much precious minutes earlier than traditional pulse oximetry monitoring alone.
In October 2006 the APSF conference set as a goal that no patient should be harmed by opioid-induced ventilatory depression in the postoperative period. To address this goal, healthcare professionals were urged to consider improvements to patient safety with continuous monitoring of both oxygenation and ventilation in patients receiving PCA or neuraxial opioids in the postoperative period.
Oridion is the global leader of innovative capnography monitoring solutions in the critical care, pain management, procedural sedation and emergency medicine settings. Oridion's innovative Microstream technology continues to be the industry gold standard for monitoring patient ventilation in this broad range of clinical settings.
Gerry Feldman, Oridion President states: "Smart Capnography is yet another step in our on-going process of innovation to improve patient safety. Ventilation monitoring is critical to improved patient safety, especially in the PCA setting. Our Smart Capnography Microstream System is the most reliable ventilation monitoring system on the market today because it relies on our uniquely sensitive detection of carbon dioxide - the only parameter that directly measures gas exchange, true ventilation and the earliest indicator of respiratory distress."
Mr. Feldman went on to say that there is a growing body of scientific and clinical evidence that indicates there is a significant risk of serious injury from patient controlled analgesia (PCA) and other opioids in the post-operative period. " Not only has the Joint Commission included recommendations on the use of improved monitoring of ventilation, the APSF has recently released its view that: ...the recognition of patients at increased risk for ventilatory depression and utilization of appropriate continuous monitors such as end tidal carbon dioxide and pulse oximetry, would improve patient safety during pain management in the post-op period."
Currently the new SARA software is pending FDA 510 (k) clearance.
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.
Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.
Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.
For further information please contact:
Gerry Feldman, President
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations (Israel), Phone +972-2-589-9159
Frank Justin, Director of Marketing (US), +1-781-354-8073
Address: Oridion Systems Ltd.
P.O. Box 45025
91450 Jerusalem, Israel
|SOURCE Oridion Systems Ltd.|
Copyright©2007 PR Newswire.
All rights reserved